|
Dr.Saporito has spent the last 15 years in positions of increasing responsibility in the pharmaceutical industry. From 1991 to 2002, Dr. Saporito was Scientist at Cephalon Inc. in the Departments of Neurobiology and Pharmacology. At Cephalon, Dr. Saporito was the lead pharmacologist in the discovery of CEP-1347, a neuroprotective kinase inhibitor that reached Phase III clinical trials for Parkinson's disease. While at Cephalon, Dr. Saporito and Dr. Reaume collaborated on a number of projects involving molecular and cellular mechanisms of neurodegeneration.From 2002 to 2004, Dr. Saporito was Group Leader in Biology at Locus Pharmaceuticals, a computational drug design company. In this role he led various preclinical programs targeting oncological, inflammatory and neurological therapeutic endpoints. Dr. Saporito has extensive experience with a wide variety of animal models of diseases encompassing inflammation, metabolic disease, neurological disorders and cancer.Dr. Saporito received his Ph.D. in Pharmacology from the Philadelphia College of Pharmacy and Science (currently The University of Sciences of Philadelphia) and continued his postdoctoral studies at UMDNJ-Robert Wood Johnson Medical School under the direction of Dr. Richard Heikkila. | 